Supplements
Valerian: root preparations, subjective versus measured sleep, conflicting trials, European medicinal categories, sedation, and safety gaps
On this page
Valerian usually means preparations from the underground parts of Valeriana officinalis. Evidence for sleep problems is inconsistent. Some studies report benefit, while others do not confirm a meaningful primary-outcome advantage. A plant’s history as a sleep aid does not establish that every extract works for chronic insomnia or has the same safety profile.[1]
Different sleep measures answer different questions
| Measure | Meaning |
|---|---|
| Sleep-quality questionnaire | How participants describe their sleep.[5] |
| Sleep latency | Time until sleep begins.[5] |
| Actigraphy | Movement-based estimates of sleep.[5] |
| Global self-assessment | An overall perception, separate from the main endpoint.[4] |
Root material and extracts are different exposures
EMA describes cut or powdered root, fresh-root juice and liquid or dry extracts. Extraction uses a solvent to select constituents, followed by partial or complete solvent removal. A tea, mixed-herb capsule and specified extract therefore cannot automatically borrow each other’s clinical results. The plant name alone does not define the preparation.[2]
The main sleep-quality result was not significant
For the predefined meaningful improvement in reported sleep quality, approximately 29% improved with valerian versus 21% with placebo. The estimated difference was 7.5 percentage points, with a 95% confidence interval from −0.9 to 15.9. That interval includes no difference; the primary comparison did not establish superiority.[4]
A favorable later impression does not replace a negative primary endpoint
A final global self-assessment favored valerian, while other sleep comparisons were uncertain. The paper reports unadjusted multiple comparisons. A favorable secondary perception must retain that context rather than being presented as success on the main endpoint. Complete missing-data, subgroup and preparation-equivalence appraisal remains outstanding.[4]
Eligibility, incomplete follow-up and sponsorship matter
Participants were aged 18–50, with limits on symptom severity and several medical and medicine exclusions. OmniActive Health Technologies supported the study. The selected original abstract, eligibility and funding passages were inspected; full analysis of missing participants, multiple endpoints and sponsor influence remains pending. These findings cannot certify every extract or severe chronic insomnia.[5]
EMA distinguishes well-established and traditional medicinal use
EMA’s public summary describes well-established use for a specific ethanolic dry extract in mild nervous tension and sleep disorders. It uses the traditional-use pathway for other defined preparations. These are preparation-specific regulatory conclusions; the summary excludes ordinary supplements and foods. They cannot establish equal effectiveness of every valerian product sold online.[2]
Sedation and longer-term safety need attention
NCCIH describes possible headache, digestive symptoms, mental dullness and vivid dreams, with poorly established long-term and reproductive safety. Combining a sedating herb with alcohol or sedative medicines raises additional concerns. Rare reports and combination products need their own assessment; a short favorable trial cannot guarantee indefinite or pregnancy safety.[1]
What does a calming mechanism actually tell us?
GABA is a chemical messenger involved in inhibition of nerve activity. The historical NIH fact sheet discusses several possible valerian constituents and GABA-related mechanisms; it does not identify one established active ingredient explaining all clinical effects. A laboratory action helps generate a hypothesis. It cannot tell us whether a particular commercial extract meaningfully improves insomnia, what amount reaches a human brain, or whether long-term treatment is worthwhile.[6]
Evidence & uncertainty
A large Norwegian study missed its main sleep-quality endpoint; a newer small extract trial reported favorable findings. Preparations, populations, follow-up and analyses differed.[4][5]
Selected-source overview · Independent review pendingPublished questions
Does the valerian plant name establish that a tea and every extract are interchangeable?
Selected-source overview · Independent review pending. Read the evidence context.
The preparations differ.[2]
Evidence behind this answer
- Valerianae radix: herbal medicinal product
agency herbal medicine assessment · Date not stated
Original indexed public-summary and document-listing passages inspected; direct clinical-passages retrieval failed, full assessment not appraised · Indexed public summary: specified medicinal categories/preparations and March 2026 summary/review listing
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did all 6,894 valerian review participants contribute to its pooled sleep-quality analysis?
Selected-source overview · Independent review pending. Read the evidence context.
That analysis used 1,065 participants.[3]
Evidence behind this answer
- Valerian root in treating sleep problems and associated disorders: a systematic review and meta-analysis
systematic review · 2020
Original review summary and selected methods/results inspected; no independent full-text appraisal · 2020 full abstract and figures: review-wide versus endpoint-specific totals and preparation hypotheses
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Were 434 randomized and 405 analyzed in the Norwegian valerian trial’s detailed flow?
Selected-source overview · Independent review pending. Read the evidence context.
Yes; the denominators differ.[4]
Evidence behind this answer
- A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia
randomized trial · 2007
Original publisher abstract and selected methods inspected, with original indexed detailed participant flow; complete trial appraisal pending · 2007 original abstract/methods and indexed participant flow: primary versus secondary results and denominators
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the Norwegian valerian trial meet its main sleep-quality superiority endpoint?
Selected-source overview · Independent review pending. Read the evidence context.
It did not.[4]
Evidence behind this answer
- A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia
randomized trial · 2007
Original publisher abstract and selected methods inspected, with original indexed detailed participant flow; complete trial appraisal pending · 2007 original abstract/methods and indexed participant flow: primary versus secondary results and denominators
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a favorable valerian secondary self-assessment replace a negative main endpoint?
Selected-source overview · Independent review pending. Read the evidence context.
The endpoints must remain separate.[4]
Evidence behind this answer
- A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia
randomized trial · 2007
Original publisher abstract and selected methods inspected, with original indexed detailed participant flow; complete trial appraisal pending · 2007 original abstract/methods and indexed participant flow: primary versus secondary results and denominators
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did all 80 randomized participants enter the newer valerian efficacy assessment?
Selected-source overview · Independent review pending. Read the evidence context.
Seventy-two completed and were included.[5]
Evidence behind this answer
- Standardized extract of Valeriana officinalis improves overall sleep quality in human subjects with sleep complaints: a randomized, double-blind, placebo-controlled clinical study
randomized trial · 2024
Original abstract, selected eligibility/measurement and funding passages inspected; complete trial-level appraisal pending · 2024 issue, 2023 online: 80 randomized, 72 included in efficacy assessment, eligibility and funding
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does EMA assign the same medicinal evidence category to every valerian preparation?
Selected-source overview · Independent review pending. Read the evidence context.
It distinguishes specified preparations.[2]
Evidence behind this answer
- Valerianae radix: herbal medicinal product
agency herbal medicine assessment · Date not stated
Original indexed public-summary and document-listing passages inspected; direct clinical-passages retrieval failed, full assessment not appraised · Indexed public summary: specified medicinal categories/preparations and March 2026 summary/review listing
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do short valerian trials establish indefinite or pregnancy safety?
Selected-source overview · Independent review pending. Read the evidence context.
Those questions remain incompletely studied.[1]
Evidence behind this answer
- Valerian: Usefulness and Safety
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Identity, inconsistent sleep evidence, adverse effects and long-term/reproductive gaps
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a GABA-related mechanism prove valerian works?
Selected-source overview · Independent review pending. Read the evidence context.
No. A plausible nerve-signaling mechanism is a reason to test a preparation. It does not establish a clinically useful sleep effect, an effective product specification, or long-term safety.[6]
Evidence behind this answer
- Valerian: Health Professional Fact Sheet
agency supplement explanation · 2013
Selected original official indexed passages inspected; direct retrieval failed; document is historical rather than a 2026 evidence update · Constituents and hypothesized GABA-related mechanisms; historical fact sheet updated 2013
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can a sleep tracker settle whether valerian helps?
Selected-source overview · Independent review pending. Read the evidence context.
The older-women trial used movement estimates alongside laboratory sleep recordings and self-reports, without establishing benefit. A single home tracker result cannot reproduce a blinded comparison or establish causation.[7]
Evidence behind this answer
- A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia
randomized trial · 2009
Original indexed methods/results inspected; direct full-text retrieval unavailable; independent full-text appraisal not completed · Randomized crossover study; sixteen older women; subjective, PSG and actigraphy outcomes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Sixty included studies did not mean sixty trials of one sleep endpoint
Shinjyo and colleagues’ 2020 review included 60 studies with 6,894 participants. Its subjective sleep-quality meta-analysis used ten studies with 1,065 participants, while the anxiety analysis used eight with 535. The larger total describes the review’s broader evidence set, rather than the denominator of each pooled efficacy result.[3]
The review proposed explanations for inconsistent findings
The authors suggested that extract quality, chemical instability and whole-root versus extract differences could explain some inconsistency. These are explanations requiring evaluation, rather than proof that every whole-root product works or that negative trials used the wrong herb. A preparation-specific hypothesis should not become a universal product recommendation.[3]
No severe events observed does not establish universal safety
The review described no severe adverse events in its included participants and a favorable overall interpretation. Its full abstract and selected figure descriptions were inspected. Complete trial-level bias, sponsor-role, search-cutoff and uncommon-harm appraisal remain pending; a dated review is not an exhaustive search through 2026.[3]
The Norwegian trial used television recruitment and online diaries
Oxman and colleagues’ 2007 trial recruited through a national television program and collected data online. The detailed participant flow reports 434 randomized and 405 contributing post-treatment diary data to the analysis. Participants received valerian or placebo for two weeks after a diary run-in period. Randomized and analyzed denominators must be distinguished.[4]
The newer trial studied a small, selected population
A trial published online in 2023 and in a 2024 issue randomized 80 adults with mild sleep complaints for eight weeks. Seventy-two completed the study and were included in efficacy assessments. It reported better questionnaire scores and selected sleep measurements with a standardized extract, including instrument-based findings in a subgroup.[5]
A revised summary date is not a new trial
The EMA listing records a March 2026 public-summary update alongside an ongoing periodic-review process. That administrative or explanatory update should not be described as a new clinical experiment. The full assessment and national product authorizations were not independently appraised here.[2]
An additional trial measured sleep in several different ways
Taibi and colleagues studied sixteen older women with insomnia in a randomized, blinded crossover trial. The study compared valerian with placebo using participant reports, polysomnography and actigraphy. Polysomnography records physiological sleep signals; actigraphy estimates sleep from movement. The trial did not establish improvement across these measurements. Its small, selected population limits precision and generalization, but the disagreement with favorable subjective studies is useful: feeling that sleep improved and objectively measured sleep are related questions, not interchangeable outcomes.[7]
References
- Valerian: Usefulness and Safety
Agency condition or prevention explanation
NCCIH · Content/publication date: not stated
Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
Cited sections: Identity, inconsistent sleep evidence, adverse effects and long-term/reproductive gaps - Valerianae radix: herbal medicinal product
Agency herbal medicine assessment
EMA HMPC · Content/publication date: not stated
Accessed: 2026-10-09 UTC · Original indexed public-summary and document-listing passages inspected; direct clinical-passages retrieval failed, full assessment not appraised
Cited sections: Indexed public summary: specified medicinal categories/preparations and March 2026 summary/review listing - Valerian root in treating sleep problems and associated disorders: a systematic review and meta-analysis
Systematic review
Shinjyo N, Waddell G and Green J · Content/publication date: 2020
Accessed: 2026-10-09 UTC · Original review summary and selected methods/results inspected; no independent full-text appraisal
Cited sections: 2020 full abstract and figures: review-wide versus endpoint-specific totals and preparation hypotheses - A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia
Randomized trial
Oxman AD and colleagues · Content/publication date: 2007
Accessed: 2026-10-09 UTC · Original publisher abstract and selected methods inspected, with original indexed detailed participant flow; complete trial appraisal pending
Cited sections: 2007 original abstract/methods and indexed participant flow: primary versus secondary results and denominators - Standardized extract of Valeriana officinalis improves overall sleep quality in human subjects with sleep complaints: a randomized, double-blind, placebo-controlled clinical study
Randomized trial
Shekhar HC and colleagues · Content/publication date: 2024
Accessed: 2026-10-09 UTC · Original abstract, selected eligibility/measurement and funding passages inspected; complete trial-level appraisal pending
Cited sections: 2024 issue, 2023 online: 80 randomized, 72 included in efficacy assessment, eligibility and funding - Valerian: Health Professional Fact Sheet
Agency supplement explanation
NIH Office of Dietary Supplements · Content/publication date: 2013
Accessed: 2026-10-13 UTC · Selected original official indexed passages inspected; direct retrieval failed; document is historical rather than a 2026 evidence update
Cited sections: Constituents and hypothesized GABA-related mechanisms; historical fact sheet updated 2013 - A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia
Randomized trial
Taibi DM and colleagues · Content/publication date: 2009
Accessed: 2026-10-13 UTC · Original indexed methods/results inspected; direct full-text retrieval unavailable; independent full-text appraisal not completed
Cited sections: Randomized crossover study; sixteen older women; subjective, PSG and actigraphy outcomes
Scope & review
- Population
- Readers exploring valerian; mild sleep complaints, selected insomnia trials and reproductive/medication contexts are distinguished
- Exposure or intervention
- Root preparations, regulatory categories, subjective/objective sleep measures and sedative concerns
- Comparison
- Source-specific symptom, care, screening or comparator settings
- Outcomes
- Sleep quality, latency, differing trial findings and uncertain longer-term clinical benefit
- Timeframe
- Selected two- and eight-week trials, a dated 2020 review and a 2026 EMA summary listing
- Jurisdiction
- Selected US/UK agency and US/European professional guidance; jurisdiction and eligibility differences are labeled
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-09 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.
- 2026-10-13 UTC: Added original-study comparisons and practical reader questions while preserving existing anchors; independent expert review remains incomplete.
What this article still leaves open
- Updated sleep guideline/review reconciliation, full trial-level bias, sponsor roles, preparation equivalence and missing-data analysis remain outstanding.
- Long-term use, withdrawal reports, combined herbal preparations, reproductive safety and other indications need separate expansion.
- Qualified review, personal sleep diagnosis and supplement, sedative or insomnia treatment regimens are not supplied.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.